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Abstract. 2-[lSF]fluoro-2-deoxy-D-glucose positron emis- 
sion tomography (FDG-PET) is a promising imaging 
procedure for detecting primary and metastatic cancer in 
the lungs. We have, however, failed to detect some small 
tumors in the lower lobes of the lungs. This study aimed 
to determine whether increase 18F background activity in 
the dependent lower lungs is present, which could make 
lesion detection more difficult. We measured the stan- 
dardized uptake values (SUVs) for FDG of normal lung 
remote from the nodular lesion in 16 patients with newly 
diagnosed untreated lung lesions stronlgy suspected to 
represent non-small cell lung cancers. In addition, 15 pa- 
tients with known or suspected primary breast cancers 
without pulmonary lesions were included as control sub- 
jects. After PET transmission images of the thorax were 
obtained, approximately 370 MBq of FDG was injected 
intravenously and imaging was immediately begun. Pa- 
tients were supine throughout the study. SUVs were de- 
termined with images obtained 50-70 min after FDG in- 
jection. Regions of interest (ROIs) of 6x6 pixels were 
positioned over normal lung in anterior, mid, and poste- 
rior portions of upper, middle, and lower lung fields. 
Thus, as many as 18 ROIs were positioned in each pa- 
tient. The SUVs of the posterior portion were signifi- 
cantly higher than those of the anterior and mid portions 
in the population of 31 cases (P <0.001). Also, the mean 
SUV of the lower lung field was significantly higher 
than the SUVs of the upper and middle lung fields in 
this population (P <0.01). This pattern was seen among 
the two groups of 16 patients suspected of having lung 
cancer and 15 control subjects. Background 18F activity 
was highest in posterior and lower lung in these patients. 
The maximum value of mean SUV observed in normal 
posterior lower lung was 0.804_0.230 (41% greater than 
the mean SUV in the anterior upper lung), which is in 
the range of the apparent SUV for a 5-mm lung lesion, 
with higher SUV, due to recovery coefficient issues. 
Thus this phenomenon could contribute to occasional 
false-negative lesions in those areas. Increased blood 
flow and FDG delivery and also scatter from heart and 
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liver may contribute to the increased lower tung back- 
ground activity. Regional differences in normal lung 
FDG uptake are significant and should be considered 
when interpreting pulmonary PET studies in patients 
with suspected primary or metastatic lung cancer. 
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Introduction 
Lung cancer is a leading and growing cause of morbidity 
and death in men and women throughout the world. To 
achieve cure, it is important to detect lung cancer in its 
early stages. Most diagnostic procedures such as com- 
puted tomography (CT) and magnetic resonance imag- 
ing depend on anatomical change, so it is not easy to dif- 
ferentiate benign from malignant pulmonary lesions es- 
pecially when they are small and/or solitary. In addition, 
the lungs represent a major site for metastases from 
many types of cancer. 
Glucose metabolism of cancer cells is generally in- 
creased [1-3]. 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is 
a positron-emitting glucose analogue, and following in- 
travenous injection, FDG accumulates rapidly in many 
malignant tumors [4]. Positron emission tomography 
(PET) using FDG yields metabolic information which 
can assist in tissue characterization. FDG-PET is a 
promising imaging technique in differentiating malig- 
nant from benign pulmonary nodules and in detect- 
ing/characterizing metastatic tumors to lung and lymph 
nodes. However, we recently failed to detect several 
small malignant metastatic lesions in the lower lung 
field in patients with melanoma, a tumor which general- 
ly has very high levels of glucose metabolism [5']~. To de- 
termine whether this occasional difficulty in detecting 
small lung lesions is due to increased background 18F ac- 
tivity in the lower lungs, we measured regional uptake of 
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FDG in varying regions of clinically normal lungs retro- 
spectively. 
Materials and methods 
Patients" and subjects. Sixteen patients (11 men and five women) 
with newly diagnosed untreated lung lesions strongly suspected to 
represent non-small cell lung cancers were included in this study. 
Patients ranged in age from 42 to 76 years (mean_+SD, 61.3_10.1). 
None had a history of diabetes or heart failure or had obvious on- 
going pulmonary infection, though most had a history of cigarette 
smoking. The control subjects consisted of 15 women with known 
or suspected primary breast cancers without pulmonary nodules or 
cardiovascular disease (age range 37-68 years; mean_+SD, 53.3_+ 
9.8). 
FDG production. 18F was produced with a T.C.C. model CS-30 
cyclotron (Cyclotron Corporation of America, Berkeley, Calif.) by 
the acceleration of protons into an H21ao target. FDG of high spe- 
cific activity ( >3000 Ci/mmol) was produced by means of nucle- 
ophilic fluorination [6]. Purity was assessed by means of thin-lay- 
er chromatography and high-performance liquid chromatography. 
Methods of production were in accordance with those for an in- 
vestigational new drug registered with the U.S. Food and Drug 
Administration. 
PET scanning. PET images were acquired with an ECAT 921/EX- 
ACT scanner (CTI, Knoxville, Tenn., distributed by Siemens 
Medical Systems, Iselin, N.J.) for 14 patients and 15 control sub- 
jects. For two patients PET was performed with an ECAT 931/08 
scanner (CTI). The scanning protocol was similar to one we have 
previously described for imaging of breast, genitourinary tract 
cancers, and lymphomas [7-9]. We obtained 47 transverse planes 
of 3.4-mm thickness encompassing a 16.0-cm axial field of view 
with the ECAT 921 scanner. Fifteen transverse planes with a 6.75- 
mm thickness and a 10.3-cm axial field of view were obtained 
with the ECAT 931 scanner. 
Patients were fasted for at least 4 h before imaging. Transmis- 
sion scanning with a germanium-68 ring or rod source was per- 
formed at two levels of the thorax. These images generally includ- 
ed the whole thorax for the ECAT 921 scanner. After the transmis- 
sion images were obtained, we injected approximately 370 MBq 
of FDG intravenously and began emission imaging. We obtained 
17 dynamic images from the time of injection until 60 rain after 
injection at the primary imaging level. These images included six 
10-s frames, three 20-s frames, two 90-s frames, one 5-rain frame, 
and five 10-rain frames. For the second attenuation-corrected im- 
aging level, we obtained static images at 60-70 rain after injec- 
tion. Patients were supine throughout the study. Since this was a 
retrospective study, data from the prone position were not ob- 
tained. 
Quantitative image analysis. Images were reconstructed with a 
128x128 matrix by using a filtered back-projection algorithm with 
a Harming filter cut-off value of 0.3. The voxel size of the ECAT 
921 scanner was 4.2x4.2x3.4 mm, while for the ECAT 931 scan- 
ner it was 4.7x4.7x6.75 mm. The reconstructed x-y resolution was 
approximately 10 mm full-width at half-maximum in plane for 
both scanners. The reconstructed z-axis resolution was about 5 
mm for the ECAT 921 scanner and 7.5 mm for the ECAT 931 
scanner. The FDG standardized uptake values (SUVs) were deter- 
mined for images obtained 50-70 min after FDG injection. SUV, 
Fig. 1. Multiple 6x6 pixel ROIs are positioned in the anterior, 
mid, and posterior portions of the upper, middle, and lower lung 
fields. ROIs were positioned first in transmission images then 
copied onto spatially registered emission images at the same level. 
The arrow indicates the intense uptake of FDG in the area of a 
squamous cell carcinoma (patient 11) 
rather than the preferred SUV lean, was obtained as statistical 
comparisons were by paired test in the same patients and because 
patients were generally not obese [10]. Quantitation of FDG up- 
take by normal lung was performed with a computerized analysis 
system (IVAS). First of all, a 6x6-pixel region of interest (ROI) 
was positioned over normal lung in anterior, mid and posterior 
portions of the upper (aortic arch level), middle (carinal level) and 
lower lung fields in the transmission images. Then, these ROIs 
were copied to the spatially registered emission images at the 
same level. Thus, as many as 18 ROIs were positioned in each pa- 
tient (Fig. 1). We did not include any pulmonary lesions, myocar- 
dium or chest wall within these ROIs. SUVs were calculated from 
two 10-min acquisitions (50-60 min post injection and 60-70 min 
post injection). The relation between the levels at which SUVs 
were measured and time after injection is shown in Table 3 for 
each patient as a part of the imaging summary. Analysis of vari- 
ance (ANOVA) with repeated measures (post hoc test was per- 
formed by Scheffe's F test) was employed for the comparison of 
SUVs in anteroposterior and craniocaudal locations. For the com- 
parison of the SUVs between the right and left lobes, the paired t- 
test was performed. Statistical results were considered to be sig- 
nificant when P <0.05. P values of the paired t-test are two-tailed. 
Results 
Clinical  and histologic f indings of the patients and con- 
trol subjects are shown in Tables 1 and 2. All  of  the pa- 
tients were smokers (patient 2 was a passive smoker). 
Mild emphysematous  changes were seen on CT scan in 
6 of the 16 patients suspected of having lung cancer. Ac- 
cording to the pu lmonary  funct ion tests, four patients 
had mild airway obstruct ion (patients 6, 8, 13, and 16). 
No patient  suffered from heart failure at the t ime of the 
PET study. Of the control subjects, only two were smok- 
ers and none  had cl inical ly evident  respiratory or cardiac 
abnormali t ies  at the t ime of PET. Imaging  informat ion is 
summarized in Table 3. 
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Tab le  1. Clinical  and  h is to logic  f indings  in 16 pat ients  suspec ted  o f  hav ing  p r imary  lung  cancer  
Pat ient  Age / s ex  P u l m o n a r y  nodu le  His to logic  f ind ing  S m o k i n g  Base l ine  F V C  FEV 1 Hear t  
no. his tory CPD (%)a (%)a fai lure? 
1 44 /M Lef t  lower  lobe I n f l a m m a t o r y  + E m p h y s e m a  b 100 100 No 
p s e u d o t u m o r  
2 69/F G r a n u l o m a  _c N o n e  85 88 No 
3 42 /M G r a n u l o m a  + E m p h y s e m a  b 104 103 No 
4 58 /M Large  cell c a r c inoma  + E m p h y s e m a  b 100 69 No 
5 65 /M S q u a m o u s  cell + N o n e  82 86 No 
ca r c i noma  
6 56 /M A d e n o c a r c i n o m a  + E m p h y s e m a  b 75 59 No 
7 76/F A d e n o c a r c i n o m a  + N o n e  101 97 No 
8 58/F N o n - s m a l l  cell type  + None  72 61 No 
ca rc inoma  
9 71/F S q u a m o u s  cell + None  90 87 No 
ca rc inoma  
10 61 /M Smal l  cell c a r c inoma  + E m p h y s e m a  b 88 61 No 
11 57/F S q u a m o u s  cell + None  108 82 No 
ca r c i noma  
12 70 /M Smal l  cell c a r c inoma  + None  91 78 No 
13 63 /M S q u a m o n s  cell + None  78 65 No 
ca r c i noma  
14 50 /M S q u a m o u s  cell + None  - - No  
ca r c i noma  
15 65 /M N o n - s m a l l  cell type + E m p h y s e m a  b 84 62 No  
ca rc inoma  
16 75 /M A d e n o c a r c i n o m a  + None  72 64 No 
Righ t  upper  lobe 
Bilateral  lower lobe 
Lef t  uppe r  lobe 
R igh t  lower  lobe 
Righ t  middle  lobe 
Righ t  upper  lobe 
Righ t  upper  lobe 
R igh t  lower  lobe 
Lef t  h i l u m  
Righ t  middle /  
lower lobe 
Lef t  l ingula  
Righ t  upper  lobe 
Righ t  upper  lobe 
R igh t  upper  lobe 
Lef t  upper  lobe 
CPD,  Chron ic  p u l m o n a r y  disease;  FVC,  forced vital  capaci ty;  
FEV 1, forced expira tory v o l u m e  in 1 s 
a Values o f  FVC and FEV 1 are expressed  as a percen tage  o f  the  
predic ted va lue  
b Mi ld  e m p h y s e m a t o u s  changes  obse rved  by  C T  scan 
c Pass ive  s m o k e r  
Tab le  2. Clinical  and  h is to logic  f ind ings  in 15 control  subjects  suspec ted  or k n o w n  to have  p r imary  breast  cancer  wi thout  p u l m o n a r y  le- 
s ion  
Subject  Age / sex  His to logic  f ind ing  Smok ing  Base l ine  FVC FEV 1 Hear t  
no. h is tory  CPD (%)a (%)a fai lure? 
1 C 63/F A d e n o c a r c i n o m a  - None  - - No  
2 C 46/F Ducta l  c a r c i noma  - None  - - No  
3 C 59/F Ducta l  c a r c i noma  - None  - - No  
4 C 37/F S a rcoma  - None  - - No  
5 C 59/F Lobular  c a r c i noma  - None  - - No  
6 C 44/F Ducta l  c a r c i noma  + None  - - No  
7 C 57/ f  Adel~ocarc inoma - None  - - No  
8 C 46/F Negat ive  for cancer  - None  - - No  
9 C 43/F F i b r o a d e n o m a  - None  - - No  
10 C 66/F Fibrocyst ic  change  - None  - - No  
11 C 64/F Negat ive  for cancer  - None  - - No  
12 C 55/F Lymphofo l l i cu la r  hyperp las ia  + None  - - No  
13 C 68/F Negat ive  for cancer  - None  - - No  
14 C 44/F b -- A s t h m a  92% 95% No 
15 C 49/F Cys t  - None  - - No  
C, Control ;  CPD,  chronic  p u l m o n a r y  disease;  FVC,  forced vital  
capaci ty;  FEV1, forced expira tory  v o l u m e  in 1 s 
a Values o f  F V C  and FE V 1 are expressed  as a percen tage  o f  the  
predic ted va lue  
b Pathological  d iagnos is  was  not  obta ined  for this  subject  
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Table 3. Summary of imaging information 
for 31 subjects a Patient Scanner SUV SUV Subject Scanner SUV SUV 
no. 50-60 b 60-70 b no. 50-6@ 60-70 b 
1 921 Lo Up, M 1 C 921 M, Lo Up 
2 921 Up, M, Lo - 2 C 921 M, Lo Up 
3 921 Up, M, Lo - 3 C 921 M, Lo Up 
4 921 Up, M, Lo - 4 C 921 M, Lo Up 
5 921 Up, M, Lo - 5 C 921 M, Lo Up 
6 921 Up, M Lo 6 C 921 M, Lo Up 
7 921 Up, M Lo 7 C 921 Lo Up, M 
8 931 Up - 8 C 921 M, Lo Up 
9 921 Up, M, Lo - 9 C 921 M, Lo Up 
10 931 M, Lo - IOC 921 Up, M, Lo - 
11 921 Up, M, Lo - 11 C 921 M, Lo Up 
12 921 Up, M, Lo - 12 C 921 M, Lo Up 
13 921 Up, M - 13 C 921 Lo Up, M 
14 921 Up, M Lo 14 C 921 M, Lo Up 
15 921 Up, M Lo 15 C 921 M, Lo Up 
16 921 Up, M Lo 
SUV 50-60, SUV data obtained from 50 to 60 rain post injection; SUV 60-70, SUV data 
obtained from 60 to 70 min post injection; Up, upper lung field; M, middle lung field; Lo, 
lower lung field; C, control 
a The entire lung field was not imaged for patients 8, 10, and 13 
b The levels at which SUVs were measured are indicated 
Table 4. SUVs in various regions of nor- 
mal lung as measured in all 31 subjects Anterior portion Mid portion Posterior portion Overall 
Upper lung 0 .569+0 .199  0 .515+0.218 0 .663+0.176 0.583-+0.207 
Middle lung 0.537_+0.166 0.541_+0.181 0.675_+0.252 0.584_+0.212 
Lower lung 0.639_+0.274 0 .679+0.217 0.804_+0.230 0.712_+0.249 
Right lobe 0.595_+0.247 0.573_+0.224 0.708_+0.235 0.625_+0.241 
Left lobe 0.558_+0.175 0.576_+0.209 0.719_+0.224 0.619_+0.214 
Bilateral lobe 0 .578+0.216 0.575-+0.216 0.713_+0.229 0.622_+0.228 
Values are expressed as mean-+SD 
Regional SUVs in normal lung for the entire popula- 
tion are shown in Table 4. For the entire population, 
mean SUVs were significantly different in anteroposteri- 
or locations, with P <0.01 by ANOVA with repeated 
measures [mean SUVs of the posterior portion were sig- 
nificantly higher than those of the anterior and mid por- 
tions, (P <0.01 by the post hoc test)]. Also, mean SUVs 
were significantly different in craniocaudal locations, 
with P <0.01 by ANOVA with repeated measures [mean 
SUVs of the lower lung field were significantly higher 
than those of the upper and middle lung fields (P <0.01 
by the post hoc text)]. In the paired comparison of mean 
SUVs between the right and the left lobe, no significant 
differences were observed except for the mid portion of 
the middle lung field, where the left lobe showed slight- 
ly higher FDG uptake than the right. 
Regional SUVs in normal lung for the 16 patients 
suspected of having lung cancer are shown in Table 5. In 
these 16 patients, mean SUVs were significantly differ- 
ent in anteroposterior and craniocaudal locations (P 
<0.01). Paired comparison of mean SUVs between the 
right and left lobes showed no significant difference. 
Regional SUVs in normal lung for the 15 control sub- 
jects are shown in Table 6. Mean SUVs were significant- 
ly different in anteroposterior and craniocaudal loca- 
tions, with P <0.0001 by ANOVA with repeated mea- 
sures. Significant differences were observed between up- 
per and lower lung fields, middle and lower lung fields, 
anterior and posterior portions, and mid and posterior 
portions (P <0.0001, P <0.05, P <0.001, and P <0.0001 
respectively). Paired comparison of mean SUVs between 
the right and left lobes showed no significant difference. 
In summary, SUVs of normal lung showed a ventro- 
dorsal and craniocaudal gradient in patients imaged with 
this protocol, with the mean SUV in the lower posterior 
lung being 41% greater than that in the upper anterior 
lung field. The highest SUV in normal lung was 1.418 
for the 16 patients and 1.576 for the control subjects. 
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Upper lung 0.624+_0.225 0.529_+0.258 0.711_+0.189 0.623_+0.234 
Middle lung 0.510-+0.177 0.557-+0.215 0.626_+0.253 0.563_+0.219 
Lower lung 0.627.+0.315 0.691+0.252 0.721_+0.227 0.684-+0.262 
Right l o b e  0.597-+0.281 0.591+0.283 0.682-+0.255 0.625+0.274 
Left lobe 0.561_+0.176 0.581_+0.211 0.688.+0.194 0.612_+0.201 
Bilateral lobe 0.581_+0.239 0.586_+0.248 0.685_+0.226 0.619_+0.241 
Values are expressed as mean+SD 
Anterior portion Mid portion Posterior portion Overall 
Table 6. SUVs in various regions of nor- 
mal lung in the 15 subjects suspected or 
known to have primary breast cancer 
Upper lung 0.518_+0.159 0.503-+0.179 0.618_+0.153 0.546+0.170 
Middle lung 0.564_+0.151 0.526+0.145 0.722+0.245 0.604+0.203 
Lower lung 0.647+0.247 0.670_+0.190 0.882+0.206 0.734_+0.238 
Right lobe 0.593_+0.212 0.559_+0.160 0.732_+0.215 0.628_+0.210 
Left lobe 0.556_+0.175 0.572-+0.210 0.747+0.247 0.625-+0.229 
Bilateral lobe 0.575_+0.195 0.565-+0.188 0.739-+0.230 0.626_+0.219 
Values are expressed as mean+SD 
Discussion 
FDG-PET is promising imaging procedure for detecting 
and characterizing various kinds of tumors including pri- 
mary and metastatic cancers of the lungs [11-16]. How- 
ever, we have occasionally failed to detect some small 
lung lesions in the lower lobes by FDG-PET with the 
ECAT 931 scanner [5]. These lesions were close to the 
diaphragm and liver. While scatter activity, lung motion, 
and the inferior z-axis resolution of this device, by com- 
parison with the 921 scanner, could cause these findings, 
we were concerned that the findings might be due, in 
part, to increased uptake of FDG at the lung bases, mak- 
ing lesion detection more challenging. 
Many investigators have previously examined region- 
al variations in normal lung density using CT. During 
normal tidal ventilation, there exists a significant differ- 
ence in normal lung density between dependent and non- 
dependent regions of the lung [17, 18]. In the supine po- 
sition, pulmonary density (Hounsfield units) has been 
found to slow an anteroposterior gradient (posterior is 
higher) by CT scan [i9, 20]. 
Using positron emission and transmission tomogra- 
phy, regional values of vascular and extravascular lung 
density have been measured. Schuster et al. measured re- 
gional lung density and lung water in normal and edem- 
atous lung in vivo in  supine dogs. In their study, there 
was an anteroposterior gradient (posterior was higher) in 
lung density, but the ratio of lung water to lung density 
was constant throughout the lung [21]. In a human PET 
study using inhaled carbon-11 carbon monoxide, a pro- 
nounced anteroposterior gradient (posterior was higher) 
of both lung and blood density was reported, while the 
gradient of extravascular lung density was quite small 
[22]. It is known that FDG uptake can occur into inflam- 
matory cells located within tumor and other normal tis- 
sues. Thus, while there was no obvious infectious pro- 
cess in these patients, we are not certain of the cellular 
location of the FDG uptake in the lung. 
While FDG uptake in normal lung is quite low rela- 
tive to many untreated tumors, there is clearly regional 
variability in supine humans. To the best of our knowl- 
edge, there exists no prior report on differential regional 
FDG uptake in normal lung. Similar to reports regarding 
other aspects of lung physiology, we found a significant 
ventrodorsal and craniocaudal difference in regional 
FDG uptake in the normal lungs in the reported 31 cases 
studied in the supine position. Since we  retrospectively 
analyzed regional SUVs in normal lung, data for the 
prone position were not obtained. SUVs may change 
with the time of measurement; however, the measure- 
ment interval from 50 to 70 min was short, and the loca- 
tions at which SUVs were measured were mixed. Thus, 
the significant differences in mean SUVs were not 
caused by differences in t ime.of measurement. FDG is 
transported from the blood to the tissues by a carrier-me- 
diated diffusion mechanism. Hexokinase catalyzes the 
phosphorylation of FDG to FDG-6-PO 4, and FDG-6- 
PO 4 is metabolically trapped in the tissues. Blood FDG 
activity is generally low. The tissue uptake of the FDG is 
dependent upon blood flow, glucose metabolism and tis- 
sue density. Therefore, the ventrodorsal gradient in re- 
gional pulmonary FDG uptake is probably multifactorial 
but possibly delivery related. We also should not forget 
the predominant FDG uptake in the myocardium and the 
liver. Scatter from these organs might contribute to the 
increased FDG uptake in the lower lungs. However, 
there was no significant difference in mean SUVs be- 
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tween the right and left lobes in the lower lung field; fur- 
thermore, the contribution of scatter to total image 
counts is viewed as relatively modest  in 2D PET. We 
ourselves did not see obviously high 18F activity in lung 
adjoining the heart (which generally had low activity) in 
these fasted patients, though the SUV in the mid portion 
of the left middle lung was slightly greater than that on 
the right. 
As regards lesion detectability, more study is needed 
to determine whether lower lung lesions are more diffi- 
cult to detect than those more cranially located, in the 
upper lung. Loss of count recovery can occur due to in- 
sufficient z-axis sampling and x-y- and z-axis recon- 
structed resolution elements greater than tumor size [23]. 
Our previously reported failure to detect several small 
lower lobe metastases of  melanoma with an older ECAT 
931 scanner may partly be due to its poorer z-axis reso- 
lution and sampling as compared with various newer 
scanners. The mean SUV for primary lung cancer le- 
sions is 9.44 in our institution [24]. Assuming a spheri- 
cal lesion of 5 m m  in diameter with a true SUV of 9.44 
and a reconstructed system resolution of 1 cm, the re- 
covery coefficient for such a lesion would be about 0.05 
[23]. So the measured SUV for this lesion would be 
0.472, which is lower than normal lung SUVs obtained 
from this study. This calculation supports our observa- 
tion that it is difficult to detect small lesions with many 
PET scanners, especially when such lesions are located 
in the lower and/or posterior lung fields with increased 
background activity. An additional contributing factor 
could be motion of the lungs during respiration. It is 
quite probable, however, that the somewhat higher back- 
ground activity in the posterior and/or lower lung fields 
could make the detection of small lesions more difficult 
in these locations. 
In conclusion, background laF activity is significantly 
increased in the posterior and lower lungs as compared 
with the upper and anterior lungs. This increased back- 
ground, along with other factors, may contribute to occa- 
sional false-negative findings in these areas, particularly 
for small lesions. Increased blood flow and FDG deliv- 
ery, increased blood volume, and also scatter from heart 
and liver may contribute to the increased lung back- 
ground activity. Regional differences in normal lung 
FDG uptake, while modest, are significant and should be 
considered when interpreting PET studies in patients 
with suspected primary or metastatic lung cancer. The 
regional variation in tSF uptake may be of greatest im- 
pact in assessing small lower lobe pulmonary lesions, es- 
pecially if  a high-resolution PET scanner is not used. 
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